StockWatch
·
Pharmaceuticals
Clarification16 Nov 2026, 02:54 pm

Wanbury Ltd Clarifies Business Unaffected by Recent Announcement

AI Summary

Wanbury Ltd has issued clarifications to investor queries regarding a recent announcement, stating that its business and sales remain unaffected. The company's exposure to the US market via the Tanuku facility accounts for approximately 6% of its consolidated YTD revenue, which is also unaffected. New ANDAs and filings will be managed from the Patalganga facility, a US FDA-approved API manufacturing site with no observations in its last inspection. Based on current assessments, there is no impact on the company's financial guidance or operations for FY 2026-27.

Key Highlights

  • Company business and sales are unaffected by recent developments.
  • US market exposure (Tanuku facility) is 6% of YTD revenue and unaffected.
  • New ANDAs and filings will be handled by the US FDA-approved Patalganga facility.
  • No impact expected on FY 2026-27 financial guidance or operations.